Roche Holding stock reports 54 percent lower death risk in trial
Published on 09/25/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock was valued at CHF 362.20 on the SIX Swiss Exchange on September 25, 2026, down 0.33 percent from the previous session. The latest clinical update gives the pharmaceutical group a concrete development milestone as it advances Tam-Peli with MediLink.
Trial cuts death risk by 54 percent
In a September 13, 2026 release, Roche said the phase III TAISHAN-302 study met its primary endpoint in relapsed small-cell lung cancer. Tam-Peli reduced the risk of death by 54 percent versus topotecan, with median overall survival of 13.3 months versus 9.4 months.
The result also delivered a quantified advantage on secondary measures. Median progression-free survival was 7.4 months versus 2.8 months, while the objective response rate reached 59.1 percent compared with 9.7 percent for topotecan.
H1 sales rise at constant rates
Roche generated CHF 30.36 billion in group sales in the six months ended June 30, 2026, according to Muffett Investments. Reported sales declined 1.6 percent, but sales increased 6.0 percent at constant exchange rates, showing the effect of currency movements on the reported comparison.
Core diluted EPS was CHF 10.85 in H1 2026 versus CHF 11.05 a year earlier, while core EPS grew 9.0 percent at constant exchange rates. The same analysis said Roche reconfirmed its full-year 2026 guidance for mid-single-digit sales growth and high-single-digit core EPS growth at constant exchange rates.
Stock remains below its yearly high
The September 25 value of CHF 362.20 was 3.62 percent below the 52-week high of CHF 375.80 and 43.62 percent above the 52-week low of CHF 252.20. Trading volume reached 86,980 shares, giving the session a clear market reference alongside the clinical data.
A September 24 market overview put Roche's market capitalization at CHF 352 billion and its average analyst target at CHF 375.34, according to MarketScreener. The target stood CHF 13.14 above the September 24 last close of CHF 363.20, a difference of 3.62 percent.
Roche stock trades at CHF 362.20
Roche stock stood at CHF 362.20 on the SIX Swiss Exchange on September 25, 2026, with a daily change of minus 0.33 percent. The combination of a positive phase III readout, currency-adjusted sales growth and a share price below the 52-week high leaves clinical execution and the 2026 guidance trajectory as the key measurable reference points.
Roche Holding stock at a glance
- Company: Roche Holding AG
- Ticker: ROP
- Trading venue: SIX Swiss Exchange
- Price as of September 25, 2026: CHF 362.20
- Market capitalization: CHF 352 billion as of September 24, 2026
- 52-week range: CHF 252.20-375.80 as of September 25, 2026
- Sector / Industry: Healthcare / Pharmaceuticals
